You are here: Industry Insights > DMT

News List

Psilera Raises $2.5 Million with Oversubscribed Series Seed from Leading Institutional Investors to Accelerate Clinical Pipeline Focused on DMT firstwordpharma
July 06, 2021
Psilera Inc., formerly Psilera Bioscience (“Psilera”) has secured $2,500,000 in a non-brokered series of seed preferred funding (the “Financing”). The influx of funding was led by Iter Investments with participation from Baird Inc., JLS Fund,
Urgent need for disease-modifying drugs to arrest Parkinson’s disease progression: GlobalData expresspharma
April 12, 2021
There are diverse development strategies and trends in Parkinson’s disease (PD) treatment at present, however, only a few of them address the pressing need for a disease-modifying therapy (DMT).
Multiple sclerosis trial focusing on people who can’t walk begins recruitment pharmatimes
November 20, 2020
A new trial focusing solely on multiple sclerosis patients who can’t walk is set to begin recruiting participants.
ATAI Launches Viridia Life Sciences to Develop Novel Formulations for Mental Health Conditions americanpharmaceuticalreview
July 29, 2020
ATAI Life Sciences announced the launch of Viridia Life Sciences, a wholly-owned subsidiary developing novel formulations of N,N-Dimethyltryptamine (DMT) to treat a variety of mental health disorders.
2011 to 2017 Saw Increase in Spending on DMTs for MS drugs
January 16, 2020
From 2011 to 2017, there was an increase in gross annual expenditures on multiple sclerosis (MS) disease-modifying therapies (DMTs), with increased spending mainly driven by increases in per-prescription costs, according to a study published online Januar
Prices Spike for Drugs Used to Treat Multiple Sclerosis drugs
August 28, 2019
From 2006 to 2016, the prices of self-administered disease-modifying therapies (DMTs) for multiple sclerosis increased, according to a study published online in JAMA Neurology.